Aims and Scope of Lung Cancer
Lung Cancer is a peer-reviewed medical journal published by Elsevier originally published on behalf of the International Association for the Study of Lung Cancer (until 2006). As of 2015, it is published on behalf of the International Lung Cancer Consortium, the European Thoracic Oncology Platform, and the British Thoracic Oncology Group. It includes original research and review articles of relevance to lung cancer. Less
Key Metrics
CiteScore 

9.4
Eigenfactor 

0.01 - 0.05
H-Index 

141
Impact Factor 

5 - 10
SJR 

Q1Oncology

SNIP 

1.44
Recommended pre-submission checks
Powered by 

Topics Covered on Lung Cancer
Lung Cancer Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
SJR
| Overview | |
| Publisher | ELSEVIER IRELAND LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1985 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Lung Cancer ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Lung Cancer
Lack of methodological clarity in the report of the association of cannabis use and lung cancer.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)
Immune-related markers define clinically relevant prognostic subgroups in thymic epithelial tumors.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)
Upfront management of brain metastases in oncogene‑addicted NSCLC - An EORTC survey.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)
Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)
Lack of methodological clarity in the report of the association of cannabis use and lung cancer.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)
Immune-related markers define clinically relevant prognostic subgroups in thymic epithelial tumors.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)
Upfront management of brain metastases in oncogene‑addicted NSCLC - An EORTC survey.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)
Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)
Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.
- 1 Jul 2026
- Lung cancer (Amsterdam, Netherlands)